Expertise in
17
conditions

Dr. Gerardo Colon-Otero

Oncology
FL - Cancer
4500 San Pablo Rd S, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
FL - Cancer
4500 San Pablo Rd S, 
Jacksonville, FL 

Overview

Gerardo Colon-Otero is an Oncologist practicing medicine in Jacksonville, Florida.

Dr. Colon-Otero is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Splenectomy.

He is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 11 clinical trials. Dr. Colon-Otero is currently accepting new patients.

Graduate Institution

University Of Puerto Rico School Of Medicine

Specialties

Oncology

Licenses

Internal Medicine in FL

Hospital Affiliations

Mayo Clinic

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

FL - Cancer
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
MC210501 Differences in Immunological Effects of Vitamin D Replacement Among Black/ African American (AA) Prostate Cancer Patients With Localized Versus Metastatic Disease
MC210501 Differences in Immunological Effects of Vitamin D Replacement Among Black/ African American (AA) Prostate Cancer Patients With Localized Versus Metastatic Disease
Enrollment Status: Recruiting
Publish Date: June 08, 2026
Intervention Type: Other, Dietary supplement, Procedure
Study Phase: Early Phase 1
Acceptance and Completion Rate of Free HPV Vaccination Among Underserved Adult Patients (Age 18-45)
Acceptance and Completion Rate of Free HPV Vaccination Among Underserved Adult Patients (Age 18-45)
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Other
Study Phase: Phase 4
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: December 11, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Gemcitabine Hydrochloride, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Enrollment Status: Completed
Publish Date: December 05, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Bevacizumab, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

55 Total Publications

Concordance of folate receptor expression in ovarian cancer over time: A single-institution retrospective study.
Concordance of folate receptor expression in ovarian cancer over time: A single-institution retrospective study.
Journal: Gynecologic oncology reports
Published: June 10, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

FL - Cancer

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-914-5419
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Attia is an Oncologist practicing medicine in Jacksonville, Florida. Dr. Attia is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, Angiosarcoma, and Thyroidectomy. Dr. Attia is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Foran is an Oncologist practicing medicine in Jacksonville, Florida. Dr. Foran is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Colonoscopy. Dr. Foran is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sikander Ailawadhi is an Oncologist practicing medicine in Jacksonville, Florida. Dr. Ailawadhi is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Colonoscopy. Dr. Ailawadhi is currently accepting new patients.

Frequently Asked Questions about Dr. Gerardo Colon-Otero

How do I make an appointment with Dr. Gerardo Colon-Otero?

You can book an appointment with Dr. Gerardo Colon-Otero by calling their office at 904-914-7532. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gerardo Colon-Otero a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gerardo Colon-Otero is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gerardo Colon-Otero specialize in?

While Dr. Gerardo Colon-Otero is a Oncology, they have specific expertise in Ovarian Cancer, Testicular Yolk Sac Tumor, and Virilizing Ovarian Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Gerardo Colon-Otero participate in research or clinical trials?

Yes. Dr. Gerardo Colon-Otero has published 55 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Gerardo Colon-Otero's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gerardo Colon-Otero accept my insurance?

Dr. Gerardo Colon-Otero accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 904-914-7532 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Colon-Otero's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile